AGILERA PHARMA AS: årsregnskap 2024 vs 2023
Grew 122879% on revenue, weaker earnings
approved 2025-03-12; registry 2025-07-23; journal 2025 688190
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for AGILERA PHARMA AS. Revenue 290.8k NOK → 357.64m NOK (+122879.0%). Net result -8.32m NOK → -34.75m NOK. Equity 49.77m NOK → 15.02m NOK.
On the constructive side: revenue rose; cash rose. Pressures included: operating result weakened; net result weakened; equity eroded.
Also worth watching: paid-in equity reduced; payroll increased; cogs moved. All figures are taken from the published annual accounts for AGILERA PHARMA AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 290.8k NOK to 357.64m NOK (+122879.0% YoY). Calculated
-
↑
Cash rose
Bank deposits 8.40m NOK → 19.09m NOK (+127.4% YoY). Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -10.06m NOK → -28.99m NOK (op. margin -3459.9% → -8.1%). Calculated
-
↓
Net result weakened
Net result -8.32m NOK → -34.75m NOK (net margin -2860.5% → -9.7%). Calculated
-
↓
Equity eroded
Book equity 49.77m NOK → 15.02m NOK (equity ratio 31.5% → 10.1%). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 49.77m NOK → 15.02m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 4 117 NOK → 4.10bn NOK (1% → 1148% of revenue). Calculated
-
·
COGS moved
COGS / varekostnad 2 127 NOK → 2.20bn NOK (+103199473.7% YoY). Calculated